Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/113429
Title: COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study
Authors: Gaio, Vânia
Santos, Ana João
Amaral, Palmira
Faro Viana, João
Antunes, Isabel
Pacheco, Vânia
Paiva, Artur 
Pinto Leite, Pedro
Antunes Gonçalves, Lígia
Araújo, Lucília
Silva, Adriana
Dias, Carlos
Kislaya, Irina
Nunes, Baltazar 
Machado, Ausenda
Keywords: COVID-19; epidemiology; occupational & industrial medicine; public health
Issue Date: 2-May-2023
Publisher: BMJ Publishing Group
Project: The data of the study were originally collected as part of the project ‘Developing an infrastructure and performing vaccine effectiveness studies for COVID-19 vaccine in the EU/EEA’ (Contract ECD.11486 Lot3 (HCW) and amendment Nº ECD.11486), and the Enhanced laboratory support to perform assessment of vaccine effectiveness against SARS-CoV- 2 infection (ECD.12175) and the ‘Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza’, funded by the European Centre for Disease Prevention and Control through a service contract with Epiconcept (ECD.12609). 
Serial title, monograph or event: BMJ open
Volume: 13
Issue: 5
Abstract: Objectives Healthcare workers (HCWs) were the first to be prioritised for COVID-19 vaccination. This study aims to estimate the COVID-19 vaccine effectiveness (VE) against SARS-CoV- 2 symptomatic infection among HCWs in Portuguese hospitals. Design Prospective cohort study. Setting and participants We analysed data from HCWs (all professional categories) from three central hospitals: one in the Lisbon and Tagus Valley region and two in the central region of mainland Portugal, between December 2020 and March 2022. VE against symptomatic SARS-CoV- 2 infection was estimated as one minus the confounder adjusted HRs by Cox models considering age group, sex, self-reported chronic disease and occupational exposure to patients diagnosed with COVID-19 as adjustment variables. Results During the 15 months of follow-up, the 3034 HCWs contributed a total of 3054 person-years at risk, and 581 SARS-CoV- 2 events occurred. Most participants were already vaccinated with a booster dose (n=2653, 87%), some are vaccinated with only the primary scheme (n=369, 12.6%) and a few remained unvaccinated (n=12, 0.4%) at the end of the study period. VE against symptomatic infection was 63.6% (95% CI 22.6% to 82.9%) for HCWs vaccinated with two doses and 55.9% (95% CI −1.3% to 80.8%) for HCWs vaccinated with one booster dose. Point estimate VE was higher for individuals with two doses taken between 14 days and 98 days (VE=71.9%; 95% CI 32.3% to 88.3%). Conclusion This cohort study found a high COVID-19 VE against symptomatic SARS-CoV- 2 infection in Portuguese HCWs after vaccination with one booster dose, even after Omicron variant occurrence. The small sample size, the high vaccine coverage, the very low number of unvaccinated individuals and the few events observed during the study period contributed to the low precision of the estimates.
URI: https://hdl.handle.net/10316/113429
ISSN: 2044-6055
2044-6055
DOI: 10.1136/bmjopen-2022-068996
Rights: openAccess
Appears in Collections:I&D ICBR - Artigos em Revistas Internacionais

Show full item record

SCOPUSTM   
Citations

1
checked on Apr 15, 2024

WEB OF SCIENCETM
Citations

1
checked on Apr 2, 2024

Page view(s)

27
checked on Apr 24, 2024

Download(s)

7
checked on Apr 24, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons